Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses whether Harry Styles had a hair transplant, with opinions divided on whether he changed his hairstyle or underwent a procedure. It also touches on the use of medication and surgery as treatments for hair loss.

A 20-year-old male is unsure how to interpret his bloodwork results and whether he should take finasteride for hair loss. His bloodwork shows borderline high levels of albumin and testosterone, and high progesterone, but normal levels of other hormones.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Hair systems are a popular solution for hair loss, offering impressive transformations with manageable maintenance and cost. Some users prefer hair systems over medications like Minoxidil or Finasteride, while others express concerns about the permanence and visibility of these systems.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

A 57-year-old man uses a hair system, not a hair transplant, and likely had cosmetic procedures. Discussions include the effectiveness of hair systems and finasteride side effects.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Dutasteride might be better for hairline due to varying levels of 5AR activity in scalps. Genetic tests can determine if finasteride is enough or if dutasteride is needed.

A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

AB de Villiers' hair restoration methods, including hair transplants and possibly a hair system or wig. Opinions vary on the success and appearance of his hairline.

The conversation discusses a hair loss treatment tier list, ranking treatments like minoxidil, finasteride, and scalp massages based on efficacy, convenience, and safety. Users express disagreement with the rankings, particularly questioning the placement of dutasteride and hair transplants.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.

Topical treatments like minoxidil and finasteride are preferred for hair loss due to ease of use and natural appearance. Hair systems are considered high-maintenance and less genuine.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

Harry Kane's hairline appears stable despite his family history of baldness, leading to speculation about his use of finasteride or other treatments. Some users discuss similar cases of slowed or halted hair loss in other individuals, attributing it to genetics or potential treatments.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.